Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• S&P downgrades Cable One to ’B+’ on weakening broadband outlook
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering